Spectral AI, Inc. (NASDAQ: MDAI) announced that it has secured an additional $31.7 million in non‑dilutive funding from the Biomedical Advanced Research and Development Authority (BARDA). The new tranche brings the total BARDA commitment to $86.6 million, with a potential ceiling of $150 million under the contract, and is part of a broader partnership that has already delivered $54.9 million in earlier funding.
The infusion is earmarked to accelerate the development of the company’s DeepView® System, an AI‑driven multispectral imaging platform that provides objective, real‑time assessments of burn‑wound healing potential. BARDA’s support will fund “additional feature aspects” such as total body surface area mapping and advanced analysis algorithms, which are critical for meeting the regulatory milestones required for FDA market authorization and for positioning the system for use in mass‑casualty burn incidents.
Spectral AI is currently awaiting a determination of market authorization from the U.S. Food and Drug Administration. The BARDA contract modification not only supplies the capital needed to advance the DeepView platform but also signals confidence from a federal agency in the technology’s potential to improve patient outcomes and reduce healthcare costs in emergency, trauma, and burn‑center settings.
Financially, the company reported a net loss of $3.6 million in Q3 2025, with revenue falling 25.1% quarter‑over‑quarter. The loss reflects substantial R&D expenditures and the company’s ongoing investment in the DeepView platform. The new BARDA funding will help offset these costs, extend the company’s cash runway, and reduce the need for equity dilution at a time when the company is preparing for FDA clearance.
The DeepView system addresses a significant market need: an estimated 1.1 million Americans suffer burn injuries each year, many of whom require emergency department or burn‑center care. By providing rapid, objective assessments of wound healing potential, the platform could streamline clinical decision‑making, reduce unnecessary interventions, and lower overall treatment costs. The BARDA investment therefore not only supports product development but also positions Spectral AI to capture a sizable share of the burn‑care market once regulatory approval is obtained.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.